South San Francisco, CA, United States of America

Jamie Harue Hirata

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2021-2024

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Jamie Harue Hirata: Innovator in Immunoconjugate Therapies

Introduction

Jamie Harue Hirata is a notable inventor based in South San Francisco, CA. He has made significant contributions to the field of immunotherapy, particularly in the treatment of B-cell proliferative disorders. With a total of 2 patents to his name, Hirata is recognized for his innovative approaches in medical treatments.

Latest Patents

Hirata's latest patents focus on the methods of using anti-CD79b immunoconjugates. These patents detail methods for treating B-cell proliferative disorders, specifically Follicular Lymphoma and Diffuse Large B-Cell Lymphoma. The immunoconjugates he developed comprise anti-CD79b antibodies combined with additional therapeutic agents, showcasing his commitment to advancing cancer treatment.

Career Highlights

Jamie Harue Hirata is currently employed at Genentech, Inc., a leading biotechnology company known for its focus on innovative medicines. His work at Genentech has allowed him to collaborate with other talented professionals in the field, further enhancing his contributions to medical science.

Collaborations

Some of Hirata's notable coworkers include Andrew G Polson and Shang-Fan Yu. Their collaborative efforts have played a crucial role in the development of new therapeutic methods and innovations in the field of immunotherapy.

Conclusion

In summary, Jamie Harue Hirata is a distinguished inventor whose work in immunoconjugate therapies has the potential to significantly impact the treatment of B-cell proliferative disorders. His innovative patents and collaborations reflect his dedication to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…